

SOURCE: Angiochem



October 03, 2016 07:00 ET

## Angiochem to Present at ESMO 2016 Congress

MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a proffered paper oral presentation during the Central Nervous Systems Tumours session at the ESMO 2016 Congress in Copenhagen, Denmark from October 7-11, 2016. Angiochem's presentation will take place on October 7th.

"ESMO is a premiere conference that brings together oncology professionals from around the globe to share updates on groundbreaking cancer research," said John Huss, Executive Chairman of Angiochem. "As such, we are honored to be chosen to present and look forward to sharing our insights at this important event."

Angiochem is focused on developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases.

Date: October 7  
Time: 16:45-17:00  
Presenter: Dr. Shou-Ching Tang, MD, PhD  
Abstract #: 324O  
Title: ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study

### About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.


Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit <http://www.angiochem.com>.

---

## Contact Information

**For more information, please contact:**

Crystal Quast  
Bullseye Corporate  
647-529-6364  
[Quast@BullseyeCorporate.com](mailto:Quast@BullseyeCorporate.com)



[View Full Site](#)

**About Marketwired**

[Marketwired News](#)  
[Community Builders](#)  
[Privacy](#)  
[Site Map](#)  
[Accessibility](#)

**Products**

[Marketwired Resonate](#)  
[Marketwired Influencers](#)  
[News Distribution](#)  
[IR/PR Newsroom \(Impress\)](#)  
[Media Database \(Mediahub\)](#)

**Resources**

[Brochures](#)  
[Case Studies](#)  
[E-Books / Tip Sheets](#)  
[Webinars / Videos](#)

**Newsroom**

[All News](#)  
[Headlines Only](#)  
[Advanced Search](#)  
[RSS Newsfeeds](#)  
[Hot Off the Wire](#)  
[Personal Beat](#)  
[CASL Compliance](#)

**Connect With Us**



**MARKETWIRED IS NOW PART OF NASDAQ**

Copyright ©2016 Nasdaq, Inc. All rights reserved. [Legal](#)